Description: Almost half of recent FDA approvals have been for orphan drugs. This trend is expected to continue in 2023. Orphan drugs are priced more than 30 times higher than non-orphan drugs, therefore their cost burden in aggregate has the potential to overwhelm the budgets of payers, especially that of smaller health plans. Hear how the cost impact analysis for smaller health plans require different considerations than for a larger health plan when modeling the impact of rare diseases.

Description: Come discuss how reinsurers can work side by side with insurer to better develop products, and lift in the areas that reinsurers have more experience, help matching products with distributions (or vice versa) and provide advanced technologies associated with tools and software. The speakers will also present Direct to Consumer plan from various points of view, i.e., distributors, carriers, and reinsurers. Some case studies will also be presented where traditional reinsurers and asset-intensive reinsurers helped insurers bring products to life.

Description: Join us as we summarize the impacts of recent studies from 2022, which update individual disability incidence rates and analyze the impact of the COVID-19 pandemic. Also, we will look at expectations for the disability insurance market. By attending this session, attendees will: - Identify the impact of recent experience adjustments to incidence rates. - Understand the impact of the COVID-19 pandemic on disability coverage. - Discover emerging issues likely to influence disability coverage in upcoming years.

Description: The session is based on an article of the same name featured in the January, 2023 issue of Health Watch. It gives a step-by-step method of how to apply the average paid PMPM method to calculate IBNR with zero run-out, as opposed to current methods, which generally require a three-month run-out period. Methods for obtaining confidence intervals for the IBNR estimates will also be discussed.

Description: Hear a summary of the discussion from the Health Section's Pharmacy Partnership Forum in March 2023 entitled 'Reimagining Pharmacy Financing' where a multi-disciplinary group of clinicians, health economists, academics, and actuaries met and discussed the following questions: How do we define the value of prescription drugs? How do we measure the value of prescription drugs? How do we scalably and meaningfully apply the answers?

Description: As long-term care enters into its fifth decade, the product continues to evolve. Current trends as well as innovative product designs pose many challenges as carriers seeks to model long-term care.

Description: As VM-22 becomes the new standard for statutory valuation of non-variable annuities, insurers must navigate a range of implementation challenges and strategic considerations. This session will provide attendees with a comprehensive roadmap for preparing for VM-22, addressing critical questions that will shape a successful transition: What are the key considerations when deciding between early adoption and waiting until the end of the transition period? How will reserve levels shift under the new framework, and what strategies can help mitigate financial volatility? What models, tools, and analyses are needed not only to comply but also to interpret results, manage risks, and help leadership gain confidence in the results?

Description: Actuarial funding of OPEB plans is primarily a public sector phenomenon due to the different regulations and tax laws that impact private sector organizations in the US. OPEB funding started to gain momentum with the implementation of GASB Statement 45 in the mid to late 2000s.

Description: Session 2B: Pharmacy Risk Mitigation - Pricing, Programs, Pools, and Performance Guarantees

Description: The surge in interest rates over the past few years presents opportunities for life insurers to enhance their Asset and Liability Management (ALM) positions through asset rebalancing to narrow the duration gap and secure higher risk-adjusted yields. This webcast introduces a robust, efficient and readily-executable, liability-driven strategic asset allocation (SAA) framework and implementation considerations. At the conclusion of the webcast, attendees will learn about the key objectives and practical considerations for a successful SAA.